U.S. markets close in 4 hours 25 minutes
  • S&P 500

    4,236.46
    -10.98 (-0.26%)
     
  • Dow 30

    34,251.45
    -228.15 (-0.66%)
     
  • Nasdaq

    14,109.52
    +40.10 (+0.29%)
     
  • Russell 2000

    2,333.77
    -2.04 (-0.09%)
     
  • Crude Oil

    71.38
    +0.47 (+0.66%)
     
  • Gold

    1,866.40
    -13.20 (-0.70%)
     
  • Silver

    28.07
    -0.08 (-0.29%)
     
  • EUR/USD

    1.2127
    +0.0021 (+0.17%)
     
  • 10-Yr Bond

    1.4870
    +0.0250 (+1.71%)
     
  • GBP/USD

    1.4111
    -0.0005 (-0.04%)
     
  • USD/JPY

    109.9870
    +0.3520 (+0.32%)
     
  • BTC-USD

    40,614.39
    +4,727.37 (+13.17%)
     
  • CMC Crypto 200

    1,008.72
    +39.88 (+4.12%)
     
  • FTSE 100

    7,160.44
    +26.38 (+0.37%)
     
  • Nikkei 225

    29,161.80
    +213.07 (+0.74%)
     

Why Crispr's Gene-Editing Jump Wasn't Enough To Help Vertex Stock

·2 min read
Why Crispr's Gene-Editing Jump Wasn't Enough To Help Vertex Stock
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Vertex Pharmaceuticals and Crispr Therapeutics appeared Friday to be making progress on a cure for two blood diseases. But only CRSP stock popped.